EGFR and non-small cell lung carcinoma: This prospective phase II multicenter, open‐label, single‐arm trial aims to evaluate the efficacy and safety of afatinib and bevacizumab used as combination therapy for patients with NSCLC with mutations in the EGFR gene previously treated with osimertinib.